Pixantrone News
Most Popular Pixantrone Story
Cell Therapeutics calls retreat on bloodied pixantrone app
Two years after Cell Therapeutics ($CTIC) took one of the worst regulatory beatings of the decade at the time the FDA and its experts rejected the company's cancer drug pixantrone, the Seattle-based Read more...
Latest Headlines
- January 30, 2012
- December 3, 2010
- September 15, 2010
- March 22, 2010
- February 18, 2010
- February 8, 2010
- February 4, 2010
- June 2, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
